Parabilis Medicines Inc., a clinical-stage biopharmaceutical company, is expected to begin trading on the Nasdaq Global Select Market, under the ticker symbol "PBLS", today, June 10, 2026.
The company has priced its IPO of 33.50 million shares of its common stock for $20.00 per share. The offering, which is scheduled to close on or about June 11, 2026, is expected to rake in gross proceeds of about $670 million.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com